Nonetheless, the mechanisms by which recurrent genetic mutations in AML, such as NPM1, FLT3-ITD, IDH1/2, and TP53 can modulate the immune microenvironment in AML, are steadily being elucidated (Figure 1). The gene discussed is TP53; the disease is acute myeloid leukemia.